 |
|
|
| |
MK-5172, a Second Generation HCV NS3/4A Protease Inhibitor is Active Against Common Resistance Associated Variants (RAVs) and Exhibits Cross-Genotype Activity
|
| |
| |
Reported by Jules Levin
HEP DART 2011, December 4-8th 2011, Kauai, HI, USA
RJO Barnard, D Graham, A Acosta, Z Guo, JA Howe, R Ogert, M Miller, D Hazuda, D Olsen, S Ludmerer, JM Strizki
Merck & Co., Inc., Whitehouse Station, NJ, USA
|
| |
|
|
|
|
|
